Berlin, Germany
Berlin, Germany

Time filter

Source Type

News Article | April 13, 2017
Site: globenewswire.com

ALBUQUERQUE, N.M., April 13, 2017 (GLOBE NEWSWIRE) -- The Albuquerque March of Dimes has named TriCore Reference Laboratories' Chief Administration Officer, Dr. Nick Dayan, as the 2017/2018 Chair of the Albuquerque March for Babies. TriCore is also the signature sponsor of this year's event. Dr. Dayan said of being chosen the Chair of the event, "I am so honored to be named the Chair of this marvelous event. By supporting the March for Babies program, we as a community have the ability to affect our newborns for a lifetime." The March for Babies will be held on Saturday, May 6, 2017 at Johnson Field on the UNM Campus. Registration will be at 10:00AM and the walk starts at 11:30AM. Please go to: bit.ly/marchforbabiesABQ for more information or to register to be a participant. Nearly 4 million babies are born annually in the US. All babies, whether they are born early or on time benefit from advances in prenatal and postpartum care made possible by the March of Dimes. Since 1970, March for Babies has been the biggest fundraiser for the March of Dimes in Albuquerque – last year's event raised $169,000 with the donations going to support the March of Dimes local efforts as well as support the five national Prematurity Research Centers. Lori Medik, Executive Director of Market Development for the March of Dimes, stated, "March for Babies is an incredible community event that allows us to focus attention on prematurity, birth defects, and infant mortality. Annually, in New Mexico 25,800 babies are born. Of these babies, 2,448 are born preterm, 782 are born with a birth defect, and 139 die before reaching their first birthday. While not everyone has a direct mission connection, everyone is affected by prematurity, birth defects, and infant mortality. Preterm birth alones costs our state $126 million a year, approximately $26 billion nationally. We care about all babies and March for Babies is an opportunity for each of us to make a difference." About March of Dimes The March of Dimes is the leading nonprofit organization for pregnancy and baby health. For more than 75 years, moms and babies have benefited from March of Dimes research, education, vaccines, and breakthroughs. About TriCore Reference Laboratories TriCore Reference Laboratories is a clinical reference laboratory providing a complete range of services to health care professionals across the Southwest as well as pathology consultation services to clinicians across the country. For more information, visit www.tricore.org


News Article | May 8, 2017
Site: globenewswire.com

MIAMI, May 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017, after the close of the U.S. financial markets on Tuesday, May 9, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 9, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


News Article | May 1, 2017
Site: www.marketwired.com

ALBUQUERQUE, NM--(Marketwired - May 01, 2017) - TriCore Reference Laboratories' CEO Khosrow Shotorbani will be a keynote speaker at this week's Executive War College on Laboratory and Pathology Management in New Orleans, Louisiana. The international conference showcases innovations by leading laboratory organizations worldwide and helps laboratory administrators and pathologists learn practical methods for improving the performance and financial success of their laboratories. Shotorbani will speak at a general session on Tuesday, May 2, on the future of clinical lab services and opportunities for labs to prosper in the future state of healthcare. Shotorbani will provide insights on how TriCore is developing and providing enriched lab services that add new value for physicians, payers and, ultimately, patients in New Mexico. Shotorbani said, "TriCore and New Mexico are serving as an incubator for the future clinical laboratory business model, reshaping the way healthcare is delivered. I am proud to share our story on the international stage." TriCore representatives, Shotorbani as well as VP of IT, Aron Seidman, and members of the Enterprise Clinical Solutions team, Kathleen Swanson and Monique Dodd, will also present in a full-day, post-conference workshop on Clinical Lab 2.0 as part of Project Santa Fe. Project Santa Fe includes leaders from five clinical laboratory operations across the country: Henry Ford Health System, Geisinger Health System, Kaiser Permanente Northern California Health Systems, Northwell Health Laboratories, and TriCore Reference Laboratories. The coalition was established both to provide thought leadership and to help develop the evidence base for the valuation of clinical laboratory services in the next era of American healthcare. TriCore Reference Laboratories is a clinical reference laboratory founded and headquartered in Albuquerque, NM that provides over 1,700 full-service, state-of-the-art laboratory tests to health care professionals and their patients. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, and instrument testing. For more information, visit tricore.org. For more information on the Executive War College visit executivewarcollege.com


The blood culture test market is categorized on the basis of methods, products, applications, end users, and regions. The global blood culture tests market is projected to reach USD 4,768.9 million by 2021 from USD 3,252.6 million in 2016, at a CAGR of 8.0%. Major factors contributing to the growth of this market include growing number of sepsis cases and high cost of treatment, increase in prevalence of infectious diseases, rapidly rising aging population, increase in product approvals and launches, increase in demand for rapid diagnostic techniques, and high incidence of bloodstream infections. Complete report on Blood Culture Tests Market spread across 249 Pages, Profiling 11 Companies and Supported with 300 Tables and 50 Figures is now available at http://www.reportsnreports.com/reports/377270-blood-culture-test-market-by-method-manual-automated-product-consumables-instrument-application-aerobic-anaerobic-yeast-fungi-end-user-hospital-reference-laboratory-clinical-laboratory-academic-research-institute-forecast-to-2019.html The relatively untapped Asian region provides an array of growth opportunities for blood culture test market. A large population base, rapid urbanization, increase in blood stream infection (BSI), rising prevalence of infectious diseases, rising aging population, increasing product availability, and technological advancements are some of the factors responsible for growth of this market. North America dominates the blood culture tests market in 2016, followed by Europe. However, Asia is projected to grow at the highest CAGR during the forecast period, owing to high incidence of sepsis and government initiatives to increase awareness on the disease, increasing demand for effective diagnostic techniques, rising awareness about early disease diagnosis, increasing adoption of advanced technologies, rapid rise in geriatric population, and growing regulatory approvals & availability of blood culture test products in this region. Stakeholders of this Research Report are as follows Study suggests that Abbott’s PCR/ESI-MS can detect bacteria, viruses, or fungi in a short span of time when the blood culture tests market are negative. Such technological advancements will significantly contribute towards the adoption of rapid diagnostic techniques among hospital laboratories and reference laboratories, which are major end users of these instruments. Get the Sample Copy of this research In addition, the growth of the blood culture tests market in North America is driven by technological advancements and increase in demand for rapid diagnostic techniques. Various market players are focusing on new product launches to expand their product portfolios and cater to their wide customer base. Key players in the blood culture tests market include Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (U.S.), Cepheid, Inc. (U.S.), Nanosphere, Inc. (U.S.), Roche Diagnostics (Switzerland), Beckman Coulter (U.S.), Bruker Corporation (U.S.), IRIDICA (U.S.), and T2 Biosystems (U.S.). Click now for more Details, Queries, Other Information and Order this study “Blood Culture Tests Market by Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia) & End User (Hospital Laboratories, Reference Laboratories) - Global Forecast to 2021” report @ http://www.reportsnreports.com/contacts/discount.aspx?name=377270 . Global blood culture tests market is dominated by North America, followed by Europe. However, market in Asia is expected to register the highest growth rate. Factors such as high incidence of sepsis and government initiatives to increase awareness on disease, increasing demand for effective diagnostic techniques, rising awareness about early disease diagnosis. Increasing adoption of advanced technologies, rapid rise in geriatric population, and growing regulatory approvals & availability of blood culture test products in this region are contributing to high growth rate of this market segment. Explore more reports on Healthcare at http://www.reportsnreports.com/market-research/healthcare/


News Article | February 27, 2017
Site: globenewswire.com

MIAMI, Feb. 27, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the fourth quarter ended December 31, 2016 after the close of the U.S. financial markets on Wednesday, March 1, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Wednesday, March 1, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning March 1, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 80392791. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


News Article | February 21, 2017
Site: globenewswire.com

MIAMI, Feb. 21, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will participate at the 2017 RBC Capital Markets’ Healthcare Conference taking place February 22-23, 2017 at the New York Palace Hotel and at the Cowen Group’s 37th Annual Health Care Conference taking place March 6-8, 2017 at The Boston Marriott Copley Place. The 2017 RBC Capital Markets’ Healthcare Conference presentation will be webcast live on the OPKO Investor Relations page of the corporate website at www.opko.com.  To access the live webcast please log onto the OPKO website approximately fifteen minutes before the presentation to register and download any necessary audio software.  The audio presentation will be available at this link for a limited time after the live presentation. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications.  Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.


News Article | March 1, 2017
Site: globenewswire.com

MIAMI, March 01, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), reports financial and operating results for the three months ended December 31, 2016. “OPKO reached a number of important milestones during 2016,” stated Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.  “We launched RAYALDEE, the first new medicine we have developed and launched ourselves.  The commercial team is making great strides in the early days of the launch and has so far secured formulary access for 60% of all U.S. insured patients.” “Use of our innovative 4Kscore test for predicting the probability of aggressive prostate cancer increased to nearly 18,000 tests ordered in the fourth quarter.  We have now set the stage for continued, profitable growth at BioReference with a revenue cycle management program that is expected to improve financial results on an ongoing basis. “We have a number of important initiatives ahead of us in 2017 and early 2018.  We will complete the recently initiated clinical trial for our Claros POC diagnostic test for PSA and plan to file a PMA as quickly as possible upon completion.  Along with our partner, Vifor Fresenius, we plan to initiate a Phase 2 trial in dialysis patients with SHPT.  We also plan to initiate a Phase 2b trial for our SARM for the treatment of BPH, a condition that affects approximately 50 million men in the U.S., as well as a Phase 2 dose escalation study for TT401 to treat obesity and type II diabetes. “We are diligently working to complete analysis of the data from our Phase 3 clinical trial for hGH-CTP in adults and are aggressively advancing our pediatric Phase 3 clinical trial for hGH-CTP,” Dr. Frost concluded. OPKO’s senior management will provide a business update and discuss the results in greater detail  in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com. For those unable to participate in the live conference call or webcast, a replay will be available beginning March 1, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 80392791. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator to treat men with BPH. Our biologics portfolio includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (in phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance, whether we will experience continued, profitable growth at Bio-Reference, whether our revenue cycle management program will improve financial results, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be successfully completed on a timely basis or at all and whether the data from any of our trials will support approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, whether the data for the hGH-CTP study in adults will support approval of a BLA, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, increased adoption rates for the 4Kscore, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi™, hGH-CTP, TT-401, TT-701, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


News Article | October 31, 2016
Site: globenewswire.com

ALBUQUERQUE, N.M., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Lovelace Health System announced today that it has selected TriCore Reference Laboratories (TriCore) for inpatient and outpatient laboratory management services at its Albuquerque hospitals. The new agreement will begin February 21, 2017. "We are pleased to be contracting with a local, leading provider of reference laboratory services," said Ron Stern, CEO of Lovelace Health System.   While providing world-class laboratory services, TriCore is also a big part of the community in Albuquerque and New Mexico at large. Founded in 1988, TriCore is an independent laboratory headquartered in Albuquerque that provides over 1700 full-service, state-of-the-art laboratory tests to health care professionals and their patients with 98.5% of testing performed on site.   "We are honored to have been chosen by Lovelace Health System. Our common dedication to improving the way health care is delivered will enhance the lives of those in our community," said Khosrow Shotorbani, CEO TriCore Reference Laboratories. "Our commitment to this community keeps testing and jobs in New Mexico. It is a long-held belief of TriCore that laboratory testing should be done nearest to the patient as clinically appropriate and economically feasible for the best patient care. This contract allows Lovelace to maintain control over the core competency of this critical part of their ecosystem, while controlling cost and optimizing care, both now and in the future. TriCore is proud to be a part of this venture."   "Since our inception in 1998, TriCore has been providing accurate and timely laboratory results to all physicians and advanced practitioners in the region. This new agreement with Lovelace builds on our laboratory foundation as well as our new information technology platform to integrate results and improve patient care." said Dr. Crossey, CMO at TriCore.   Lovelace Health System consists of Lovelace Medical Center, Lovelace Rehabilitation Hospital, Lovelace Women's Hospital, Lovelace Westside Hospital, Heart Hospital of New Mexico at Lovelace Medical Center, Lovelace Regional Hospital-Roswell and Lovelace Medical Group. TriCore Reference Laboratories is an independent clinical reference laboratory that provides over 1,700 full-service, state-of-the-art laboratory tests to health care professionals and their patients. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, device and diagnostic instrument testing. TriCore serves global biotech firms as well as academic clients. For more information, visit tricore.org


News Article | November 3, 2016
Site: globenewswire.com

MIAMI, Nov. 03, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three months ended September 30, 2016, after the close of the U.S. financial markets on Monday, November 7, 2016. OPKO’s senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, November 7, 2016. The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. For those unable to participate in the conference call or webcast, a replay will be available beginning November 7, 2016 at 7:30 p.m. ET for a period of time. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 12830677. The replay can also be accessed for a period of time on OPKO’s website at www.opko.com. About OPKO Health OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the third-largest clinical laboratory in the U.S. with a core genetic testing business and a 420 person sales force to drive growth and sell new products, such as the 4Kscore prostate cancer test and the Claros 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for stage 3-4 CKD patients with secondary hyperparathyroidism and vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics products under development are hGH-CTP, a once weekly human growth hormone for injection (partnered with Pfizer), long acting Factor VIIa for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). OPKO has production and distribution assets in several countries abroad, strategic investments and an active business development strategy. More information is available at www.opko.com.


News Article | January 23, 2017
Site: globenewswire.com

ALBUQUERQUE, N.M., Jan. 23, 2017 (GLOBE NEWSWIRE) -- When Karissa Culbreath isn't publishing articles and presenting about infectious diseases, this Scientist is actively engaged in the community and now, preparing to be on the national stage for the children's book she authored, "Daddy's Little Girl". This February Culbreath, who is the Scientific Director for Infectious Diseases at TriCore Reference Laboratories- the largest healthcare lab in New Mexico, will trade in her lab coat for an evening gown to walk the red carpet at the NAACP Image Awards. "Every little girl has dreams of what she can be when she grows up. This story highlights the role of the encouragement and affirmations of a father in building those dreams in a young girl. From doctor to architect, teacher to firefighter, girls can be anything they want to be. Reinforcement of those dreams by the words of her father has the power to positively influence her ability to achieve those goals," says Culbreath.   In addition to telling an inspirational story, "Daddy's Little Girl" also includes suggestions for encouraging those integral father-daughter chats. "The book concludes with words of affirmation and conversation starters to help to reinforce the relationship between a father and daughter," adds Culbreath.   One dad reviewed the book saying, "This book brought a tear to my eyes. I don't always know what to say to my daughter, she is just so different from me. When we read the book, and did the affirmations at the end, we started a whole new part of our relationship."   The NAACP Image Awards show will air live on Saturday, February 11, 2017 at 9/8pm Central on TV ONE.   "Daddy's Little Girl" is available on amazon . For more information about the author, visit http://karissaculbreath.com/ Photos accompanying this release are available at:

Loading Reference Laboratories collaborators
Loading Reference Laboratories collaborators